Group 1 - The company has approved a profit distribution plan for the first half of 2025, proposing a cash dividend of 2.40 yuan per 10 shares, totaling approximately 44.20 million yuan [10][29][31] - The total share capital used for the dividend calculation is 184,160,421 shares after deducting shares held in the repurchase account [10][30] - The company reported a net profit of approximately 102.20 million yuan for the first half of 2025, with no statutory surplus reserve withdrawn [29][30] Group 2 - The company held its fourth board meeting on August 21, 2025, with all 14 directors present, and the meeting was deemed legal and effective [5][7] - The board unanimously approved the profit distribution plan and confirmed that the report's content is true, accurate, and complete [5][11] - The company has not experienced any significant changes in its operational situation during the reporting period [4][28] Group 3 - The company decided to waive its preemptive rights for a capital increase in its associate company, Beijing Hemu Biotechnology Co., Ltd., which will raise 94 million yuan [23][34] - Following the capital increase, the company's shareholding in Hemu Biotechnology will decrease from 6.76% to 5.23% [23][35] - The decision to waive the preemptive rights was made in consideration of the company's overall situation and was approved by the independent directors [37][47]
天津市依依卫生用品股份有限公司2025年半年度报告摘要